Clinical Rheumatology

, Volume 37, Issue 5, pp 1417–1420 | Cite as

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial

  • Patrick Durez
  • Karel Pavelka
  • Maria Alicia Lazaro
  • Abraham Garcia-Kutzbach
  • Robert J. Moots
  • Howard Amital
  • Marinella Govoni
  • Nathan Vastesaeger
Brief Report


GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria. This analysis included 3280 participants from the GO-MORE trial. All participants included in this analysis had high or moderate disease activity at baseline. At baseline, high disease activity was least common in Europe (71.0%), Canada (77.0%), and the Middle East (78.2%) and most common in Latin America (90.7%), South Africa (91.5%), and Asia (92.5%). Month 6 remission rates were highest in South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Higher rates of remission in each geographical region generally corresponded with lower baseline disease activity. We suspect that access to care and implementation of the treat-to-target strategy were the most important determinants, but this apparent relationship needs to be confirmed in further studies that include a statistical analysis of prognostic indicators.


Antirheumatic agents Clinical trial Geographic locations Golimumab Rheumatoid arthritis 



Medical writing was provided by Dr. Phillip Leventhal (4Clinics, Paris, France) and paid for by MSD. Statistical support was provided by Dr. Ruji Yao (MSD). The GO-MORE study and this analysis were supported by MSD.

Compliance with ethical standards

Conflict of interest

P.D. received fees for participation in speakers’ bureaus for Bristol-Myers Squibb, Samsung, Pfizer, UCB, Mundipharma, Hospira, and Eli Lilly. K.P. received honoraria for speaking and consultations from AbbVie, Pfizer, Roche, Egis, Bristol-Myers Squibb, and MSD. M.D. and N.V. are employees of MSD. All other authors declare no conflict of interest.


  1. 1.
    Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509CrossRefPubMedGoogle Scholar
  3. 3.
    Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, Hsia EC, Xu W, Baratelle A, Beutler A, Rahman MU (2011) The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 63:1200–1210CrossRefPubMedGoogle Scholar
  4. 4.
    Weinblatt ME, Bingham CO 3rd, Mendelsohn AM et al (2013) Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 72:381–389CrossRefPubMedGoogle Scholar
  5. 5.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210–221CrossRefPubMedGoogle Scholar
  6. 6.
    Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CAF, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH, on Behalf of the GO-MORE Investigators (2014) Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis 73:1477–1486CrossRefPubMedGoogle Scholar
  7. 7.
    Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am 35:745–757 vii-viiiCrossRefPubMedGoogle Scholar
  8. 8.
    Vastesaeger N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, Wollenhaupt J, Zerbini CAF, Louw I, Combe B, Beaulieu A, Schulze-Koops H, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, Durez P (2016) Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Rheumatology (Oxford) 55:1466–1476CrossRefGoogle Scholar
  9. 9.
    Alonso A, Gonzalez CM, Ballina J et al (2015) Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. Reumatol Clin 11:144–150CrossRefPubMedGoogle Scholar
  10. 10.
    Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15CrossRefPubMedGoogle Scholar
  11. 11.
    Putrik P, Ramiro S, Keszei AP, Hmamouchi I, Dougados M, Uhlig T, Kvien TK, Boonen A (2016) Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Ann Rheum Dis 75:540–546CrossRefPubMedGoogle Scholar
  12. 12.
    Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM, Sacnun MP, Soriano ER, Laurindo IM, Acevedo-Vásquez EM, Caballero-Uribe CV, Padilla O, Guibert-Toledano ZM, da Mota LM, Montufar RA, Lino-Pérez L, Díaz-Coto JF, Achurra-Castillo AF, Hernández JA, Esteva-Spinetti MH, Ramírez LA, Pineda C, Furst DE (2012) Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis Care Res (Hoboken) 64:1135–1143Google Scholar
  13. 13.
    Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, Hetland ML, Peets T, Immonen K, Maillefert JF, Drosos AA, Alten R, Pohl C, Rojkovich B, Bresnihan B, Minnock P, Cazzato M, Bombardieri S, Rexhepi S, Rexhepi M, Andersone D, Stropuviene S, Huisman M, Sierakowski S, Karateev D, Skakic V, Naranjo A, Baecklund E, Henrohn D, Gogus F, Badsha H, Mofti A, Taylor P, McClinton C, Yazici Y (2009) Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 68:1666–1672CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et CliniqueUCL Saint-LucBrusselsBelgium
  2. 2.Institute of Rheumatology (Revmatologicky Ustav)Praha 2Czech Republic
  3. 3.Instituto de Rehabilitacion Psicofisica de la Ciudad de Buenos AiresBuenos AiresArgentina
  4. 4.AGAR, UFMGuatemala CityGuatemala
  5. 5.University Hospital AintreeLiverpoolUK
  6. 6.Sheba Medical Center-Tel-HashomerRamat GanIsrael
  7. 7.MSDRomeItaly
  8. 8.MSDWoluwe-Saint-LambertBelgium

Personalised recommendations